We are live on ! Find out more
PVCT

PROVECTUS BIOPHARMACEUTICALS, INC. (DE)
PVCT

Delisted

PVCT was delisted on the 13th of October, 2016.

Back to rankings

7 hedge funds and large institutions have $24.2K invested in PROVECTUS BIOPHARMACEUTICALS, INC. (DE) in 2022 Q4 according to their latest regulatory filings, with 1 funds opening new positions, increasing their positions, 1 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

102% more capital invested

Capital invested by funds: $12K → $24.2K (+$12.2K)

0% more funds holding

Funds holding: 7 → 7 (0)

0% more first-time investments, than exits

New positions opened: 1 | Existing positions closed: 1

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 1

Holders
7
Holders Change
–
Holders Change %
0%
% of All Funds
0.11%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
–
Reduced
1
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
DT
Diversified Trust
Tennessee
-$2K
2
AA
Ancora Advisors
Ohio
-$915
Name Holding Trade Value Shares
Change 		Change in
Stake
HFBOT
1
Home Federal Bank of Tennessee
Tennessee
$10.8K – – –
LDB
2
Lee, Danner & Bass
Tennessee
$5K – – –
AW
3
Atlas Wealth
Ohio
$2.88K +$2.88K +26,620 New
LIA
4
LBMC Investment Advisors
Tennessee
$2.38K – – –
ACM
5
Academy Capital Management
Texas
$2.17K – – –
AA
6
Ancora Advisors
Ohio
$1K -$915 -7,000 -48%
DT
7
Diversified Trust
Tennessee
– -$2K -50,000 Closed

PVCT Hedge Fund Activity: Q4 2022 in Review

7 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in PROVECTUS BIOPHARMACEUTICALS, INC. (DE) (PVCT) for Q4 2022, worth a combined $24.2K — up 102% from $12K a quarter earlier.

Fund positioning in PVCT was balanced in Q4 2022: 1 fund opened new positions, 1 closed out, 0 added to existing stakes and 1 trimmed.

The largest seller was Diversified Trust, exiting entirely with an estimated $2K sold.

  • 7 institutional investors held PROVECTUS BIOPHARMACEUTICALS, INC. (DE) (PVCT) as of Q4 2022, unchanged from Q3 2022.
  • Funds reported $24.2K of PROVECTUS BIOPHARMACEUTICALS, INC. (DE) stock for Q4 2022, up 102% quarter-over-quarter.
  • 1 fund opened new PROVECTUS BIOPHARMACEUTICALS, INC. (DE) positions in Q4 2022 and 1 closed out, a net change of 0 holders.
  • The largest PROVECTUS BIOPHARMACEUTICALS, INC. (DE) seller in Q4 2022 was Diversified Trust, an estimated $2K sold.

Based on aggregated 13F filings for Q4 2022.